PMC:7600245 / 35068-35320 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T531","span":{"begin":18,"end":28},"obj":"Chemical"},{"id":"T532","span":{"begin":175,"end":177},"obj":"Chemical"},{"id":"T533","span":{"begin":183,"end":204},"obj":"Chemical"},{"id":"T534","span":{"begin":222,"end":235},"obj":"Chemical"}],"attributes":[{"id":"A531","pred":"chebi_id","subj":"T531","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A532","pred":"chebi_id","subj":"T532","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A533","pred":"chebi_id","subj":"T533","obj":"http://purl.obolibrary.org/obo/CHEBI_63726"},{"id":"A534","pred":"chebi_id","subj":"T534","obj":"http://purl.obolibrary.org/obo/CHEBI_41879"}],"text":"cokinetic booster cobicistat (combination is being marketed under the name Evotaz; 2015). Currently, it is being evaluated alone (NCT04468087; n = 189) or in combination with NA-831 (neuroprotective agent; traneurocin) or dexamethasone for the treatmen"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1063","span":{"begin":18,"end":28},"obj":"Chemical"},{"id":"1064","span":{"begin":75,"end":81},"obj":"Chemical"},{"id":"1065","span":{"begin":175,"end":181},"obj":"Chemical"},{"id":"1066","span":{"begin":206,"end":217},"obj":"Chemical"},{"id":"1067","span":{"begin":222,"end":235},"obj":"Chemical"}],"attributes":[{"id":"A1063","pred":"tao:has_database_id","subj":"1063","obj":"MESH:D000069547"},{"id":"A1067","pred":"tao:has_database_id","subj":"1067","obj":"MESH:D003907"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"cokinetic booster cobicistat (combination is being marketed under the name Evotaz; 2015). Currently, it is being evaluated alone (NCT04468087; n = 189) or in combination with NA-831 (neuroprotective agent; traneurocin) or dexamethasone for the treatmen"}